Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

M D Anderson Cancer Center to lead radiosurgery study for operable lung cancer patients

Accuray : 26 October, 2007  (New Product)
Accuray is to partner The University of Texas M D Anderson Cancer Center in Houston, Texas to launch a prospective clinical study to compare treatment outcomes in early-stage operable lung cancer.
Patients in the study will be randomly assigned to traditional surgery or CyberKnife Robotic Radiosurgery for their treatment.

In the past several years evidence has grown showing sucessful outcomes in the treatment of lung tumours with high-dose radiation delivered in three or four treatments. Study results on operable patients treated by these short courses have demonstrated survival rates and local control rates similar to those of traditional surgery. As the medical community moves toward adoption of more minimally invasive alternatives to treatment, data that compare outcomes of surgery to less invasive treatment options, such as radiosurgery, become important.

”We feel the time is right to explore less invasive alternatives for early stage lung cancer patients,” said Jack Roth, M.D, professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery at M D Anderson and the study’s principal investigator. “The results achieved with Radiosurgery appear to be comparable to those achieved with traditional surgery for early stage lung cancer patients and a randomised clinical trial is required to accurately compare results from the two. To do so, we must use a uniform platform to assure the highest possibility of cure for these patients, which is why we are partnering with Accuray to use the CyberKnife System. The results of this study may change the way lung cancer patients are treated.”

Additionally, Ritsuko Komaki, MD, professor of Radiation Oncology and program director, Thoracic Radiation Oncology and Joe Y Chang, MD, PhD, assistant professor of Radiation Oncology and Clinical Service Chief, Thoracic Radiation Oncology, are co-principal investigators on the study.

Sites from around the world will participate in this 1,200-patient study, with coordination and oversight by the M D Anderson team. The goal of the study is to compare treatment outcomes between surgery and CyberKnife Radiosurgery across a broad range of geographic healthcare markets. Patient accrual is expected to begin in early 2008.

A major factor in the success of this study is selecting the most accurate method of treatment that will maximise radiation to the tumour and minimise damage to surrounding healthy tissue. Accuray’s CyberKnife System combined with the company’s Synchrony Respiratory Tracking System and Xsight Lung Tumor Tracking System allow patients to receive a completely non-invasive treatment in three to four days through the precise delivery of high-dose radiation. While the patient lies comfortably and breathes normally, the CyberKnife System continually tracks the tumour to maximise targeting accuracy and minimise damage to surrounding healthy tissue. Treatments are performed in an outpatient setting, without the expected complications of an invasive surgical procedure.

“Over the past five years clinicians have obtained excellent outcomes treating lung cancer with CyberKnife Radiosurgery,” said Omar Dawood, MD, MPH, vice president of Clinical Development of Accuray. “We believe the CyberKnife System’s unique ability to track tumour motion and deliver radiation accurately and non-invasively make it the ideal platform for this clinical study. We are excited about this partnership with M D Anderson, a leader in cancer treatment, and the huge benefits this study’s outcomes could have for patients with lung cancer.”

M D Anderson is currently ranked number one in the USA in cancer care, according to the U.S. News & World Report’s 2007 America’s Best Hospitals report.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo